SOUTH SAN FRANCISCO, Calif., March 4, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report year-end 2013 results on Tuesday March 18th, 2014. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm ET (1:30 p.m. PT).
OXiGENE's earnings conference call can be heard live by dialing (888) 841-3431 in the United States and Canada, and +1 (678) 809-1060 for international callers, five minutes prior to the beginning of the call.
To listen to a live or archived version of the audio webcast, please log on to the Company's website, www.oxigene.com. Under the "Investors" tab, select the link to "Events & Presentations."
OXiGENE is a biopharmaceutical company developing novel therapeutics to treat cancer. The Company's is focused on developing vascular disrupting agents (VDAs) which are compounds that selectively disrupt abnormal blood vessels associated with solid tumor survival and progression. The Company's lead clinical product candidate, ZYBRESTAT®, is in development as a potential treatment for ovarian cancer, neuroendocrine tumors and anaplastic thyroid cancer (ATC). OXi4503, its second-generation product candidate, is in development for acute myeloid leukemia (AML). OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
CONTACT: Investor and Media Contact: firstname.lastname@example.org 650-635-7000